Immunovant Inc (IMVT) reported financial results for the second quarter of fiscal 2026, aligning with analyst expectations. The company posted an earnings per share (EPS) of $-0.73, matching the consensus estimate of $-0.73. Revenue remained at $0.0 billion, consistent with forecasts.
This update provides insight into Immunovant's operational performance and financial health. The company, headquartered in New York City and employing 362 full-time staff, focuses on developing therapies for autoimmune diseases. Its product pipeline includes IMVT-1402 and batoclimab, both of which are monoclonal antibodies targeting the neonatal FcRn.
Immunovant will host its earnings conference call at 8:00 a.m. ET to discuss these results further and provide additional commentary on business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance and future outlook.
Looking ahead, the company is expected to report earnings on 9 August 2026, with an EPS estimate of $-0.73 and revenue projected at $0.0 billion. The following earnings report is scheduled for 26 May 2026, with an EPS estimate of $-0.77 and revenue also expected to be $0.0 billion.